Page 39«..1020..38394041..5060..»

Category Archives: Molecular Medicine

UK research getting to bottom of COVID clots – ABC 36 News – WTVQ

Posted: September 18, 2020 at 8:56 pm

The research led by Jeremy Wood, Zach Porterfield and Jamie Sturgill in the Department of Internal Medicine; Beth Garvy in Microbiology, Immunology & Molecular Genetics; and Wally Whiteheart in Molecular & Cellular Biochemistry, suggests localized inflammation in the lungs caused by COVID-19 may be responsible for the increased presence of blood clots in patients.

The study also provides evidence suggesting the risk of thrombosis could persist after the infection clears.

The study examined the blood of 30 COVID-19 patients including 15 who were inpatients in the intensive care unit, and 15 who received care as outpatients at UKs Infectious Diseases Clinic, along with eight disease-free volunteers who acted as a control group.

Compared to baseline, the COVID-19 patients had elevated levels of tissue factor, a protein found in blood that initiates the clotting process. Patients also had reduced levels of protein S, an anticoagulant that helps prevent blood clotting.

The researchers concluded that lung inflammation caused by COVID-19 is what leads to a decrease in protein S. Thisinflammation also causes immune and possible endothelial cell activation, which leads to increased tissue factor protein.

What weve learned is that the clotting is not caused by anything systemic. Localized inflammation in the lungs is whats driving this whole process, Wood said. With an increase in tissue factor and a deficiency in protein S, COVID-19 patients get more blood clotting without the ability to shut it down or control it.

The study additionally showed that protein S levels remained low in some patients even after they tested negative for COVID-19, which suggests that blood clotting issues may persist after infection and long-term monitoring of thrombotic risk may be necessary.

Wood says this preliminary data could be a cause for concern. Certain viruses like HIV are linked to a long-term deficiency in protein S, which causes an ongoing risk of thrombosis in patients. It is not yet known if COVID-19 could cause a similar persisting protein S deficiency.

Tissue factor and protein S are good markers to monitor for long-term thrombosis risk and the data suggest that we need to be monitoring these patients because were not seeing these parameters corrected immediately, Wood said.

The research team recently received a grant from UKsCenter for Clinical and Translational Science(CCTS) to begin a longitudinal study to look at these levels in patients over the next year.

This will help answer the question: will this risk remain like it is in the HIV patients or will it go away?

The study was funded in part by anAlliance Grantthrough the College of Medicine as well as UKsCOVID-19 Unified Research Experts (CURE) Alliancethroughthe Vice President for Research and the College of Medicine and the CCTS. It was a product of collaboration between a number of different groups at UK that have been studying COVID-19.

Additional collaborators includeMartha Sim, Meenakshi Banerjee and Hammodah Alfar in the Department of Molecular and Cellular Biochemistry; Melissa Hollifield and Jerry Woodward with Microbiology, Immunology and Molecular Genetics; Xian Li with the Saha Cardiovascular Research Center; Alice Thornton with the Division of Infectious Disease; and Gail Sievert, Marietta Barton-Baxter and Kenneth Campbell with CCTS.

Link:
UK research getting to bottom of COVID clots - ABC 36 News - WTVQ

Posted in Molecular Medicine | Comments Off on UK research getting to bottom of COVID clots – ABC 36 News – WTVQ

BIS Research Report Highlights the Global Precision Medicine Market to Reach $278.61 Billion by 2030 – PRNewswire

Posted: September 18, 2020 at 8:56 pm

FREMONT, Calif., Sept. 17, 2020 /PRNewswire/ -- The global precision medicine marketis projected to reach $278.61 billion by 2030, reveals a premium market intelligence report by BIS Research. The study also highlights that the market is set to witness a CAGR of 11.13% during the period between 2020 and 2030.

The comprehensive study of the global precision medicine market by BIS Research extensively covers the following:

The detailed report is a compilation of 19 Market Data Tables and 330 Figures spread through 529 Pages and in-depth TOC on "Global Precision Medicine Market"

Besides these parameters, the report also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 1400+ products.

The BIS Research report indicates that the increasing number of genetic tests taken, the growing demand for reliable next-generation sequencing (NGS) results, the rising prevalence of infectious diseases, and the improving funding scenario in the field of precision medicine, among others, are fueling the growth of the market.

It also highlights the various emerging opportunities, such as growth in emerging nations, capitalization on the high prevalence of cancer, and the evolution of technology in healthcare, that can be leveraged by players operating in the market.

Additionally, the market intelligence report by BIS Research throws a spotlight on the key industry trends that have a humungous influence in shaping the industry going forward. Some of these trends include the emergence of advanced stabilization products, regulated vs. multimodal analysis, collaborations and partnerships, and several other key trends.

View the Report from BIS Research: Global Precision Medicine Market

Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include types of products offered, technologies used, sources used, applications, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The technology and ecosystem analysis of the global market includes data analysis on the satisfaction level of different pricing analysis of preferred instruments, accessories and components, and consumables. The study is majorly centered on the sub-segments and micro-segments of the different product markets, such as consumables and instruments. The consumables are further categorized into kits and reagents.

Emphasizing the dominance of North America in global precision medicine market in 2019 and 2020, Nitish Kumar Singh, Lead Analyst BIS Research, states, "InNorth America, several established diagnostics manufacturers are focusing on expanding their portfolio in NGS-based molecular diagnostics and are collaborating with service providers and pharmaceutical giants to co-market molecular diagnostics solutions with its complementary precision medicine solutions. Moreover, the U.S. government is undertaking a number of initiatives to develop of precision drugs and tests for oncology and non-oncology diseases and provide funds to new startups in the molecular diagnostics and precision medicine field."

Request for a Sample: https://bisresearch.com/requestsample?id=964&type=download

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 40 leading companies, market participants, and vendors. The key players profiled in the report includeAbbott Laboratories, Almac Group Ltd, Amgen Inc., ANGLE plc, Astellas Pharma Inc., Astra Zeneca PLC, ASURAGEN INC., Bio-Rad Laboratories, Inc., bioMrieux SA., Bristol-Myers Squibb Company, Cardiff Oncology, CETICS Healthcare Technologies GmbH, Danaher Corporation, Eli Lilly and Company Limited, Epic Sciences, Inc., F. Hoffmann-La Roche Ltd, GE Corporation, Gilead Sciences, Inc., GlaxoSmithKline Plc, Illumina, Inc., Intomics A/S, Johnson & Johnson Company, Konica Minolta, Inc., Laboratory Corporation of America, MDx Health, Inc., Menarini Silicon Biosystems, Inc., Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Oracle Corporation, Partek, Inc., Pfizer, Inc., QIAGEN N.V., Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi SA, Sysmex Corporation, Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific, Inc.

The report also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

How can this market intelligence report on precision medicine add value to an organization's decision-making process?

Insightful Questions Covered to Enable Companies take Strategic Decisions

Related BIS Research Market Reports:

Global NGS Sample Preparation Market - Analysis and Forecast, 2019-2025

Global Next Generation Sequencing (NGS) Market - Analysis and Forecast, 2019-2024

Global Rare Disease Diagnostics Market - Analysis and Forecast, 2018-2025

About BIS Research:

BIS Researchis a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as, custom studies, and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.

BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, Precision Medicine, and other emerging healthcare technologies, covering the entire industry spectrum. In the past 5 years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform for the past two years successfully.

Contact:

Bhavya BangaEmail: [emailprotected] BIS Research Inc.39111 PASEO PADRE PKWY STE 313,FREMONT CA 94538-1686Visit our Blog @ https://blog.bisresearch.com/ Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-researchConnect with us on [emailprotected] https://twitter.com/BISResearch

SOURCE BIS Research

Link:
BIS Research Report Highlights the Global Precision Medicine Market to Reach $278.61 Billion by 2030 - PRNewswire

Posted in Molecular Medicine | Comments Off on BIS Research Report Highlights the Global Precision Medicine Market to Reach $278.61 Billion by 2030 – PRNewswire

New molecular therapeutics center established at MIT’s McGovern Institute – MIT News

Posted: September 18, 2020 at 8:56 pm

More than 1 million Americans are diagnosed with a chronic brain disorder each year, yet effective treatments for most complex brain disorders are inadequate or even nonexistent.

A major new research effort at the McGovern Institute for Brain Research at MIT aims to change how we treat brain disorders by developing innovative molecular tools that precisely target dysfunctional genetic, molecular, and circuit pathways.

The K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience was established at MIT through a $28 million gift from philanthropist Lisa Yang and MIT alumnus Hock Tan 75. Yang is a former investment banker who has devoted much of her time to advocacy for individuals with disabilities and autism spectrum disorders. Tan is president and CEO of Broadcom, a global technology infrastructure company.This latest gift brings Yang and Tans total philanthropy to MIT to more than $72 million.

In the best MIT spirit, Lisa and Hock have always focused their generosity on insights that lead to real impact," says MIT President L. Rafael Reif. Scientifically, we stand at a moment when the tools and insights to make progress against major brain disorders are finally within reach. By accelerating the development of promising treatments, the new center opens the door to a hopeful new future for all those who suffer from these disorders and those who love them. I am deeply grateful to Lisa and Hock for making MIT the home of this pivotal research.

Engineering with precision

Research at the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience will initially focus on three major lines of investigation: genetic engineering using CRISPR tools, delivery of genetic and molecular cargo across the blood-brain barrier, and the translation of basic research into the clinical setting. The center will serve as a hub for researchers with backgrounds ranging from biological engineering and genetics to computer science and medicine.

Developing the next generation of molecular therapeutics demands collaboration among researchers with diverse backgrounds, says Robert Desimone, McGovern Institute director and the Doris and Don Berkey Professor of Neuroscience at MIT. I am confident that the multidisciplinary expertise convened by this center will revolutionize how we improve our health and fight disease in the coming decade. Although our initial focus will be on the brain and its relationship to the body, many of the new therapies could have other health applications.

There are an estimated 19,000 to 22,000 genes in the human genome and a third of those genes are active in the brain the highest proportion of genes expressed in any part of the body. Variations in genetic code have been linked to many complex brain disorders, including depression and Parkinsons disease. Emerging genetic technologies, such as the CRISPR gene editing platform pioneered by McGovern Investigator Feng Zhang, hold great potential in both targeting and fixing these errant genes. But the safe and effective delivery of this genetic cargo to the brain remains a challenge.

Researchers within the new Yang-Tan Center will improve and fine-tune CRISPR gene therapies and develop innovative ways of delivering gene therapy cargo into the brain and other organs. In addition, the center will leverage newly developed single-cell analysis technologies that are revealing cellular targets for modulating brain functions with unprecedented precision, opening the door for noninvasive neuromodulation as well as the development of medicines. The center will also focus on developing novel engineering approaches to delivering small molecules and proteins from the bloodstream into the brain. Desimone will direct the center and some of the initial research initiatives will be led by associate professor of materials science and engineering Polina Anikeeva; Ed Boyden, the Y. Eva Tan Professor in Neurotechnology at MIT; Guoping Feng, the James W. (1963) and Patricia T. Poitras Professor of Brain and Cognitive Sciences at MIT; and Feng Zhang, James and Patricia Poitras Professor of Neuroscience at MIT.

Building a research hub

My goal in creating this center is to cement the Cambridge and Boston region as the global epicenter of next-generation therapeutics research. The novel ideas I have seen undertaken at MITs McGovern Institute and Broad Institute of MIT and Harvard leave no doubt in my mind that major therapeutic breakthroughs for mental illness, neurodegenerative disease, autism, and epilepsy are just around the corner, says Yang.

Center funding will also be earmarked to create the Y. Eva Tan Fellows program, named for Tan and Yangs daughter Eva, which will support fellowships for young neuroscientists and engineers eager to design revolutionary treatments for human diseases.

We want to build a strong pipeline for tomorrows scientists and neuroengineers, explains Hock Tan. We depend on the next generation of bright young minds to help improve the lives of people suffering from chronic illnesses, and I can think of no better place to provide the very best education and training than MIT.

The molecular therapeutics center is the second research center established by Yang and Tan at MIT. In 2017, they launched the Hock E. Tan and K. Lisa Yang Center for Autism Research, and, two years later, they created a sister center at Harvard Medical School, with the unique strengths of each institution converging toward a shared goal: understanding the basic biology of autism and how genetic and environmental influences converge to give rise to the condition, then translating those insights into novel treatment approaches.

All tools developed at the molecular therapeutics center will be shared globally with academic and clinical researchers with the goal of bringing one or more novel molecular tools to human clinical trials by 2025.

We are hopeful that our centers, located in the heart of the Cambridge-Boston biotech ecosystem, will spur further innovation and fuel critical new insights to our understanding of health and disease, says Yang.

Read more:
New molecular therapeutics center established at MIT's McGovern Institute - MIT News

Posted in Molecular Medicine | Comments Off on New molecular therapeutics center established at MIT’s McGovern Institute – MIT News

Scientists outraged by White House appointees’ meddling with coronavirus information: ‘Outright egregious’ – USA TODAY

Posted: September 18, 2020 at 8:56 pm

Without masks and a vaccine, we could reach Herd Immunity from COVID-19, but deaths would skyrocket. We break down the science of it. USA TODAY

Scientists and physicians reacted with words such as aghast, despicable and outrageous over the weekend as news spread that White House appointeesinterfered with a basic national public health reportwhen it conflicted with PresidentDonald Trump'scoronavirus messaging.

Michael Caputo, the Health and Human Services assistant secretary for public affairs, acknowledged Saturday that since June, he and an adviser havescrutinized and at times pushed for changes toa weekly health report distributed by the U.S. Centers for Disease Control and Prevention.

The meddling, first reported by Politico,included efforts to stop the publication of a report last week on the use of hydroxychloroquine,a malaria drug often touted by Trump, delaya10-state study of COVID-19 infection statistics in Juneand another on the spread of coronavirus at a Georgia sleep-away camp.

The Morbidity and Mortality Weekly Report is a series of dry and sometimes dense briefupdates on public health incidents that comeout on Thursdays. They typically describeevents or topicsand are an important way for doctors and health officials to get the latest data.

Monday, members of the House Select Subcommittee on the Coronavirus Crisis sent a letter to HHS Secretary AlexAzar and CDC Director Robert Redfield requesting documents pertaining to the efforts to block the publicationof "accurate scientific reports."

"We are gravely concerned by reports showing that the Presidents political appointees at HHS have sought to help him downplay the risks of the coronavirus crisis by attempting to alter, delay, and block critical scientific reports from CDC," the letter said.

Approving a vaccine in the U.S. usually takes years, but COVID-19 vaccines are moving through in record time. What does that mean? USA TODAY

The sprint to create a COVID-19 vaccine started in January. The finish line awaits.

Dr. William Schaffner, who is on the publications editorial board, said he was aghast and appalled" by the reported attempts to delay, stop or change reports.He described the publication as a vital part of the global conversation among public health officials who track diseases and dangers.

It has been the voice of the U.S. governments health system, of integrity and scientific rigor, for years," said Schaffner, a professor and infectious disease expert at the Vanderbilt University School of Medicine in Nashville, Tennessee."Indeed, the MMWR has been a model for other countries ministries of public health for creating similar newsletters in their countries.

The interference is not just anti-science butdisinformation intended to deceive the American public, said Dr. Eric Topol, a professor of molecular medicine at the Scripps Research Institute in La Jolla, California.

This is outright egregious. Its despicable, Topol said, accusing Redfieldand otherleadersof allowing the agency to be hijacked by politics.

Coronavirus in America: Here's how the virus is spreading, state by state

What were seeing is multiple actors, important people who are just laying down, who are complicit with the anti-science machinations of the Trump administration, he said.

In an interview Saturday with The Washington Post,Caputo alleged the content of the MMRWis being politicized by the agency itself.

But in an election year, and in the time of COVID-19,its no longer unanimously scientific. Theres political content, The Post quoted Caputo as saying.

On a Facebook livestream on Sunday night, Caputo railed against what he termed"sedition" among CDC scientists, the New York Times reported Monday.They havent gotten out of their sweatpants except for meetings at coffee shops to plot how theyre going to attack Donald Trump next, the Times reported him as saying. The Facebook video has since been removed.

On Twitter,Dr. Sherri Bucher, a global health researcher, wrote,There are no words to articulate how horrific this is. Trust & credibility, shattered, overnight. MMWR has been, for a long time, one of the most reliable, steadfast, scientific resources; unquestioned veracity, impeccable reputation for quality of data/analysis. No longer.

It is not unusual for communicationpeople within the CDC to be involved in an MMWR report before publication, said Dr. Patrick Remington, a member of the journals editorial board and a former CDC staffer.

That involvement was previously restricted to officials within the agency who let political leaders know what was coming so they could be prepared with a communicationstrategy, said Remington, associate dean for public health at the School of Medicine and Public Health at theUniversity of Wisconsin-Madison.

What is unusual is the allegation that the political process is attempting to influence the scientific conclusions. And thats a concern, Remington said.

A member of the editorial board for 14 years, Remington said the body meets roughly once a year to help decide the publication's big-picture vision. Its most recent meeting was in February.

Coronavirus Watch: An American dies of COVID-19 every 2 minutes

The board is not involved in the publication's day-to-day operations, and members knew nothing about the accusations of interferenceuntil they read about them, he and others said.

Jeff Niederdeppe, another member of the MMWR editorial board and a professor of public health communicationat Cornell University, said political meddling could erode public faith and cause long-term damage to the publication.

The big issue here in my mind is the fundamental undermining of trust, he said, both in the CDC generallyand among the public health practitioners who rely on the MMWR to make policy decisions. If that very foundation is being politicized, its incredibly alarming.

Regaining trust is a challenge, he said, and should begin with an immediate response from the CDC, which has not commented on the allegations.

If the concerns are confirmed, Niederdeppe said, Id be interested in convening with the other members of the MMWR editorial board to figure out what we could do in this role.

The Notes from the Field section of the MMWR previews small investigations by state or local health departments that illustrate a specific problem.

Theyre like an alert mechanism, Schaffner said.

MMWRs have described American heat-related deaths by sex and age, top foods contributing to high-salt intake, an outbreak of tuberculosis among workers at food processing plants and drinking rates among pregnant women.

Dr. Jennifer Kates, senior vice president of the nonprofit Henry J. Kaiser Family Foundation, which focuseson health issues, described the MMWR as the go-to public health publication.

The MMWR predates the CDC, beginning as a publication of the U.S. Public Health Servicein 1878.

Kates said she was disturbed by what appears to be the insertion of politics into a well-respected scientific journal. In general, the politicization of COVID has been the enemy of public health, she said.

MMWR reports are written by CDC staff, as well as public health workers and physicians nationwide. The one- to two-page reports are known for their meticulous and careful editing, a process those who'vegone through it described as harrowing.

If youve ever been involved as a co-author of one of those reports, its painful how carefully every sentence is reviewed for scientific rigor, for precision,Schaffner said.

The Centers for Disease Control and Prevention issues the Morbidity and Mortality Weekly Report every Thursday.(Photo: Jessica McGowan, Getty Images)

Read or Share this story: https://www.usatoday.com/story/news/health/2020/09/13/covid-scientists-white-house-meddling-cdc-mmwr/5787230002/

See the rest here:
Scientists outraged by White House appointees' meddling with coronavirus information: 'Outright egregious' - USA TODAY

Posted in Molecular Medicine | Comments Off on Scientists outraged by White House appointees’ meddling with coronavirus information: ‘Outright egregious’ – USA TODAY

HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean? – The DBT News

Posted: September 18, 2020 at 8:56 pm

HTG Molecular Diagnostics Inc. [NASDAQ: HTGM] surged by $0.0 during the normal trading session on Thursday and reaching a high of $0.35 during the day while it closed the day at $0.34. The company report on September 8, 2020 that HTG Molecular Diagnostics to Present Corporate Overview at Fall Investor Conferences.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced John Lubniewski, President and CEO of HTG, will present virtually at the H.C. Wainwright 22nd Annual Global Investment Conference and at the Cantor Fitzgerald Global Healthcare Conference. Details are as follows:.

About HTG.

HTG Molecular Diagnostics Inc. stock has also gained 6.01% of its value over the past 7 days. However, HTGM stock has declined by -52.85% in the 3 months of the year. Over the past six months meanwhile, it has lost -1.16% and lost -51.28% year-on date.

The market cap for HTGM stock reached $25.48 million, with 65.76 million shares outstanding and 49.64 million shares in the current float. Compared to the average trading volume of 4.77M shares, HTGM reached a trading volume of 2065978 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Cantor Fitzgerald have made an estimate for HTG Molecular Diagnostics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 11, 2020. The new note on the price target was released on March 26, 2020, representing the official price target for HTG Molecular Diagnostics Inc. stock. Previously, the target price had yet another raise from $4.50 to $6, while Rodman & Renshaw kept a Buy rating on HTGM stock.

The Average True Range (ATR) for HTG Molecular Diagnostics Inc. is set at 0.04, with the Price to Sales ratio for HTGM stock in the period of the last 12 months amounting to 1.77. The Price to Book ratio for the last quarter was 1.22, with the Price to Cash per share for the same quarter was set at 0.44.

HTG Molecular Diagnostics Inc. [HTGM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.01. With this latest performance, HTGM shares dropped by -27.00% in over the last four-week period, additionally sinking by -1.16% over the last 6 months not to mention a drop of -56.99% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTGM stock in for the last two-week period is set at 37.10, with the RSI for the last a single of trading hit 41.28, and the three-weeks RSI is set at 37.50 for HTG Molecular Diagnostics Inc. [HTGM]. The present Moving Average for the last 50 days of trading for this stock 0.5115, while it was recorded at 0.3292 for the last single week of trading, and 0.5346 for the last 200 days.

Operating Margin for any stock indicates how profitable investing would be, and HTG Molecular Diagnostics Inc. [HTGM] shares currently have an operating margin of -102.09 and a Gross Margin at +53.60. HTG Molecular Diagnostics Inc.s Net Margin is presently recorded at -100.49.

Return on Total Capital for HTGM is now -49.79, given the latest momentum, and Return on Invested Capital for the company is -53.22. Return on Equity for this stock declined to -85.65, with Return on Assets sitting at -43.42. When it comes to the capital structure of this company, HTG Molecular Diagnostics Inc. [HTGM] has a Total Debt to Total Equity ratio set at 71.00. Additionally, HTGM Total Debt to Total Capital is recorded at 41.52, with Total Debt to Total Assets ending up at 37.72. Long-Term Debt to Equity for the company is recorded at 50.39, with the Long-Term Debt to Total Capital now at 29.47.

Reflecting on the efficiency of the workforce at the company, HTG Molecular Diagnostics Inc. [HTGM] managed to generate an average of -$172,301 per employee. Receivables Turnover for the company is 4.70 with a Total Asset Turnover recorded at a value of 0.43.HTG Molecular Diagnostics Inc.s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.10 and a Current Ratio set at 7.40.

With the latest financial reports released by the company, HTG Molecular Diagnostics Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.16/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HTGM.

There are presently around $6 million, or 34.30% of HTGM stock, in the hands of institutional investors. The top three institutional holders of HTGM stocks are: NANTAHALA CAPITAL MANAGEMENT, LLC with ownership of 5,060,160, which is approximately 0% of the companys market cap and around 0.80% of the total institutional ownership; COWEN PRIME SERVICES LLC, holding 4,579,500 shares of the stock with an approximate value of $1.57 million in HTGM stocks shares; and PERKINS CAPITAL MANAGEMENT INC, currently with $0.83 million in HTGM stock with ownership of nearly -3.68% of the companys market capitalization.

Positions in HTG Molecular Diagnostics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 17 institutional holders increased their position in HTG Molecular Diagnostics Inc. [NASDAQ:HTGM] by around 1,592,904 shares. Additionally, 17 investors decreased positions by around 3,162,056 shares, while 8 investors held positions by with 11,662,409 shares. The mentioned changes placed institutional holdings at 16,417,369 shares, according to the latest SEC report filing. HTGM stock had 7 new institutional investments in for a total of 1,062,389 shares, while 11 institutional investors sold positions of 2,750,997 shares during the same period.

More:
HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean? - The DBT News

Posted in Molecular Medicine | Comments Off on HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean? – The DBT News

Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision…

Posted: September 18, 2020 at 8:56 pm

Dublin, Sept. 18, 2020 (GLOBE NEWSWIRE) -- The "National eHealth Initiatives Advancing Global Precision Medicine Market, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

This research service analyzes the key building blocks for the precision medicine ecosystem to provide strategic imperatives and growth opportunities for key participants.

Key Issues Addressed

The study captures both the global and regional flavors for PM market opportunity realization such as: market projections, drivers and restraints, country readiness index, and major government and commercial initiatives. The study also provides live case studies and innovative business models for leading companies in the PM space.

Precision medicine is transitioning toward wider acceptance, due to mounting payer pressures and regulatory changes that are shifting pharma businesses from prescriptive to more predictive and personalized models. Emergence of value-based reimbursement models and healthcare consumerism trends are helping move the treatment model from one-size-fits-all' to a stratified and outcome-based targeted therapeutics concept called precision medicine' (PM).

Companion diagnostics (CDx) and targeted therapeutics (TRx) are going beyond oncology and spreading more toward therapeutic areas such as infectious diseases, central nervous system (CNS), and cardiovascular diseases. Despite a relatively high success rate for PM R&D assets commercialization in recent years, considerable challenges exist around proving clinical utility and a regulatory and reimbursement framework, which is rigid, decentralized, and non-uniform.

Advances in omics technologies help in identifying molecular targets with the help of molecular insights generated by datasets about the disease pathogenesis. PM informatics is the key component of the PM ecosystem. PM-cognitive analytic platforms capable of leveraging genomic, clinical, financial, and lifestyle data, while delivering actionable clinical insights at the point of care, are gaining market traction. Big Data and Artificial Intelligence (AI) are the key enablers for utilizing the full potential of PM for building predictive models based on multi-omics data, given a big hurdle in the adoption of PM is lack of technology infrastructure.

Genomic sequencing has huge potential to support the COVID-19 outbreak exploration, especially in comprehending the re-emergence of potential COVID-19 outbreaks.

In terms of geographic outlook, although the specific focus on PM research started in the United States and the EU, countries such as Canada, China, Australia, Taiwan, South Korea, Singapore, and Japan have made significant advances in recent years in this area by way of significant investments to develop in-country research and scientific expertise to improve access. Considering the infrastructure requirements for utilizing omics in clinical practice, China and Japan are beating other leading countries in terms of both research initiatives and regulations and infrastructure development.

Key Topics:

Executive SummaryKey Questions This Study Will Answer6 Big Themes for Precision MedicinePrecision Medicine - Regional Market OverviewPrecision Medicine Vendor Landscape by Major Market ClustersPrecision Medicine Readiness of Major CountriesKey InsightsPrecision Medicine in the Wake of COVID-19

Research Scope, Definitions, and SegmentationResearch ScopePersonalized Vs Precision MedicinePrecision Medicine CategoriesPatient Stratification - Data Volume, Sources, and AdoptionPrecision Medicine - Key Segments and Data Sources

Current and Future State of Precision MedicineGlobal Precision Medicine Market - Macro to Micro VisioningChanging Modalities of Innovative DrugsPrecision Medicine in the Late-stage Clinical Trials PipelineMajor Pharmacogenomics BiomarkersPrecision Medicine Vendor Landscape

Precision Medicine Market Projections (2019–2025)Scenario Contingent Projections for Core Precision Medicine SegmentForecast Assumptions for Core Precision Medicine Segment - Optimistic ScenarioForecast Assumptions for Core Precision Medicine Segment - Pessimistic ScenarioCore Precision Medicine Segment - Revenue Forecast Scenario AnalysisCore Precision Medicine Segment - Revenue Forecast by SubsegmentsForecast Assumptions - Core Precision Medicine Key Subsegments

Precision Medicine Cluster Benchmarking by Major CountriesSelect Countries’ Readiness for Precision MedicineFactors Consideration for Precision Medicine Country Readiness IndexCountry Readiness for Precision Medicine - USCountry Readiness for Precision Medicine - EU and UKCountry Readiness for Precision Medicine - APAC

Growth Opportunities in Precision MedicineMajor Growth Opportunities

Opportunity Analysis - CDx and Biomarker-based Targeted Therapeutics (TRx)Growth Opportunity 1 - CDx and Biomarkers-based TRxPrecision Medicine Clinical Trials Trends in Major RegionsTop Areas of Companion Biomarker ResearchNew Clinical Trial Designs in the Era of Precision MedicineSelect Countries’ TRx and CDx Readiness Index

Opportunity Analysis - Genomics Technologies for Precision DiagnosticsGrowth Opportunity 2 - Genomics Technologies for Precision DiagnosticsPrecision Medicine Patient Stratification by Omics/Diagnostic FactorsLevel of Adoption of Select Novel Technologies and ApproachesGenomics Technologies for Precision DiagnosticsSelect NGS Vendor LandscapeSelect Countries’ Omics Research Readiness Index

Opportunity Analysis - Precision Medicine InformaticsGrowth Opportunity 3 - Precision Medicine Informatics SolutionsPrecision Medicine Informatics Market LandscapePrecision Medicine Informatics Market SizeC2A: Xifin - Precision Medicine Informatics for MDxSelect Countries’ eHealth Readiness Index

Key Conclusions

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/lvkzh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Go here to see the original:
Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision...

Posted in Molecular Medicine | Comments Off on Global Precision Medicine Research Report 2020: Taiwan, Estonia, and Finland Emerging as Key Markets Fueling Growth Opportunities in Precision…

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune…

Posted: September 18, 2020 at 8:56 pm

DetailsCategory: Proteins and PeptidesPublished on Friday, 18 September 2020 10:55Hits: 201

- Series A led by Canaan Partners, Samsara BioCapital and The Column Group- Foundational research into cytokine structural biology and immune function licensed from Stanford University- Nils Lonberg joins founding investors on board of directors

MENLO PARK, CA, USA I September 17, 2020 I Synthekine Inc., an engineered cytokine therapeutics company, today announced the closing of an $82 million Series A financing. The financing was co-led by Canaan Partners, Samsara BioCapital and The Column Group, with participation from other undisclosed investors. Synthekine was founded by K. Christopher Garcia, Ph.D., to leverage discoveries showing that cytokines can be tuned to enhance their therapeutic effects.

Synthekine combines strengths in immunology, structural insights on cytokines and multiple engineering technologies to create optimized therapeutics against new and validated cytokine targets for the treatment of cancer and autoimmune disorders. Proceeds from this Series A financing will be used to advance Synthekines lead therapeutic programs into clinical studies, expand its discovery pipeline and hone its proprietary cytokine engineering platforms. The company currently has two lead programs in IND-enabling development: STK-012, an engineered Interleukin-2 (IL-2) partial agonist for the treatment of cancer, and the combination of STK-009 and SYNCAR-001, an orthogonal IL-2 ligand and a CD-19 CAR-T-cell therapy being studied in combination.

Cytokines have a fundamental role in the immune system and represent an enormous opportunity for innovative therapeutics. However, most cytokines broadly activate a wide range of cells that can simultaneously stimulate and suppress the immune system, making drug development against these targets challenging, said Debanjan Ray, chief executive officer of Synthekine. Chris Garcia has shown, for a wide range of therapeutically important cytokines, that cytokine efficacy and toxicity can be decoupled through structure-based protein engineering. These findings mean that many cytokines previously thought to be unsuitable as therapeutics can be transformed into safe and effective drugs. In addition to our highly differentiated IL-2-based programs, we have assembled multiple best-in-class technologies and an accomplished team to develop cytokine therapeutics by engineering them at the molecular level to enhance their activity and selectivity.

Unlocking cytokine therapeutics through unique structural biology insights

Cytokines are small, soluble proteins that are powerful regulators of the immune system and can stimulate a wide range of immune cells, primarily driven by their binding and interaction with cell surface receptors. Most cytokines are pleiotropic, meaning that a given cytokine can exert a range of responses across multiple cell types. Pleiotropy has proven to be a significant obstacle in the development of cytokine therapeutics. Existing cytokine therapeutics, such as aldesleukin (Proleukin) and interferons, demonstrate meaningful efficacy in cancer and other diseases but are limited by significant side effects.

Synthekine has licensed several cytokine programs and platforms from Stanford University. Research conducted in the Garcia lab at Stanford led to insights into the interaction of cytokines and their receptors, allowing researchers to engineer modified cytokines to deliver selective activity to particular cell types of therapeutic interest, giving them the potential for optimized efficacy, a larger therapeutic window and improved safety for patients. This research has been responsible for determining the three-dimensional structures for many different cytokine/receptor complexes, including IL-1, IL-2, IL-4, IL-6, IL-13, IL-15, IL-17, IL-23 and the three different classes of interferons.

A deep preclinical pipeline and proprietary platform

Synthekine is advancing several preclinical programs and innovative platform technologies. These include:

A collaborative company formation effort and seasoned leadership team

The founding members of Synthekines board of directors include Tim Kutzkey, Ph.D., managing partner of The Column Group; Srinivas Akkaraju, Ph.D., founding partner of Samsara BioCapital; and Julie Grant, general partner at Canaan Partners. Synthekine has also appointed biopharma veteran Nils Lonberg as an independent member of its board of directors.

Synthekines executive team is led by Debanjan Ray as chief executive officer. Mr. Ray was previously chief financial officer and head of business development at CytomX Therapeutics, where he was responsible for leading financing efforts and securing multiple strategic collaborations with major pharmaceutical companies that generated more than $400 million in upfront payments and up to $4 billion in milestones. The executive team also includes Martin Oft, M.D., as chief development officer, Rob Kastelein, Ph.D., as head of therapeutic discovery and Gregory Yedinak as senior vice president of technical operations.

Synthekines scientific advisory board is led by its founder, K. Christopher Garcia, Ph.D., professor of molecular and cellular physiology and structural biology at Stanford University School of Medicine, a Howard Hughes Medical Institute (HHMI) investigator and a member of both the National Academy of Sciences and the National Academy of Medicine.

About Synthekine

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system. For more information, visit http://www.synthekine.com.

SOURCE: Synthekine

View original post here:
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune...

Posted in Molecular Medicine | Comments Off on Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune…

2bPrecise Wins Industry Innovation Award – Bio-IT World

Posted: September 18, 2020 at 8:56 pm

Fierce Healthcare honors the precision medicine platform for clinical information management capabilities

RALEIGH, NC, UNITED STATES - Sep 16, 2020 - Fierce Healthcare released its annual Fierce Innovation Report this week, naming 2bPrecise the industrys top clinical information management solution. The intent of the awards program, according to Fierce Healthcare, is to showcase organizations that over the past 12 months have demonstrated innovative solutions that have the greatest potential to save money, engage patients, or revolutionize the industry.

Cloud-based, the 2bPrecise platform consumes molecular data from labs and clinical information from the EHR, synthesizing them into a clinical-genomic ontology. The resulting precision medicine insights are delivered to providers within their familiar workflow across any EHR. Plus, the solution is built to interact with evolving knowledge sources and care guidelines.

These unique capabilities enable health systems to leverage precision medicine insights in myriad ways - driving efficient workflows for genomics interventions, extracting population analytics, building cohorts for trial recruitment, enabling participation in research studies and more.

2bPrecise was similarly honored with the MedTech Breakthrough award as Best Overall Genomics Solution earlier this year, and the company received Microsoft Corp.s 2020 Health Innovation Award in the category of Reimagine Healthcare. Industry Wired magazine further recognized 2bPrecise as one of the Top 8 Precision Medicine Companies in the USA this year.

We are honored to receive this latest recognition from Fierce Healthcare, said 2bPrecise CEO Assaf Halevy. The entire 2bPrecise team is driven to create excellent solutions to support clinical decision making within the providers workflow - while simultaneously helping improve outcomes and the patient experience.

Additional winners announced by Fierce Healthcare include Roche (data analytics/business intelligence), Walgreens (digital/mobile health solutions), XSOLIS (financial/operational) and Centivo (population health management/patient engagement).

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM) brings the resulting precision medicine insights into a physicians EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at http://www.2bPreciseHealth.com.

Media Contact

Erica Navar

Account Executive

Aria Marketing (for 2bPrecise)

(909) 538-9541

enavar@ariamarketing.com

Originally posted here:
2bPrecise Wins Industry Innovation Award - Bio-IT World

Posted in Molecular Medicine | Comments Off on 2bPrecise Wins Industry Innovation Award – Bio-IT World

Mutation in Housekeeping tRNA Linked to Autism – Technology Networks

Posted: August 28, 2020 at 8:54 am

Within cells, molecules known as transfer RNAs, or tRNAs, play an important but unglamorous workhorse role in keeping the genetic translation process moving along from codes of DNA to functional proteins.

Because they play such a vital role in this translational housekeeping, tRNAs are plentiful.

There are hundreds of tRNA genes in mammalian cells and more than enough backup copies, just in case anything goes wrong. Yet because there are so many tRNAs, theyve been largely overlooked in the search for the roots of disease processes.

University of California San Diego scientists studying tRNAs in mice have now found that a mutation in a tRNA gene calledn-Tr20expressed only in the braincan disrupt the landscape of the entire cell, leading to a chain reaction altering brain function and behavior.

The new researchis described in the journalNeuron.

Study first author Mridu Kapur, a postdoctoral scholar working in Professor Susan Ackermans laboratory, says she and her colleagues found thatn-Tr20plays a role in the delicate balance of excitatory and inhibitory neurotransmission in the brain. A disruption in this balance has been implicated in numerous neurological diseases, including epilepsies and autism spectrum disorders.

tRNAs have generally been overlooked in the hunt for the genetic causes of disease, but recent whole genome sequencing projects have revealed that there are many variations in tRNA sequences in the human population, said Kapur. Our study suggests the enormous potential for tRNA variants to contribute to disease outcomes and phenotypic variability.

The researchers found that a loss ofn-Tr20, one of the members of a five-gene tRNA family, made mice resistant to seizures. While they note that their initial interest in this area came from the idea that a tRNA mutation could subsequently influence other gene mutations, their results not only confirm their speculations that tRNA mutations can influence other mutations, but indicate that these mutations alone can also alter brain function.

You can imagine its like a seesawif you push either way you can have problems, said Ackerman, a member of the Section of Neurobiology, Department of Cellular and Molecular Medicine and investigator at the Howard Hughes Medical Institute. Keeping balance of these two opposing forces is essential for normal function. Shifting one way or another can lead to neurological diseases. Its becoming well accepted in the autism spectrum disorder field that what we are really seeing is an imbalance of excitatory/inhibitory neurotransmission.

Ackerman says part of the reason tRNAs have been overlooked in disease investigations is because researchers commonly concentrate on mutations in unique genes. A member of a large family such asn-Tr20typically gets tossed in the genetic garbage can because they are too similar to one other.

We never knew a mutation in a multi-copy tRNA gene could do anything like this, said Ackerman. These findings make you think about people who have diseases with variable symptoms and how much this class of overlooked genes could be playing a role in their disease. So were seeing this go from a behavior, such as seizure, all the way to the molecular underpinnings causing them.

The researchers say the results are likely the tip of the iceberg and are now turning their attention to studying tRNA links to disease in tissues outside the brain.

Reference: Kapur et al. (2020).Expression of the Neuronal tRNA n-Tr20 Regulates Synaptic Transmission and Seizure Susceptibility. Neuron.DOI: https://doi.org/10.1016/j.neuron.2020.07.023.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original post:
Mutation in Housekeeping tRNA Linked to Autism - Technology Networks

Posted in Molecular Medicine | Comments Off on Mutation in Housekeeping tRNA Linked to Autism – Technology Networks

Professor/Associate Professor in Medicine Obesity and Metabolism job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY – NTNU | 223116 – Times…

Posted: August 28, 2020 at 8:54 am

About the position

At the Faculty of Medicine and Health Sciences, we have a vacancy for a 100% permanent position as Professor/Associate Professor in Medicine (Obesity and Metabolism).

The position is at theDepartment of Clinical and Molecular Medicine.

You willreportto the head of department.

Duties of the position

The appointee is expected to teach within their relevant expertise across all study programmes at the Faculty.

The person appointed must comply with the decisions about changes due to developments in the subject area, and the organizational changes that may result from decisions regarding the university's activities.

Required selection criteria

The position of Professorwithin obesity and metabolism requires that you meet the criteria in theRegulations concerning appointment and promotion to teaching and research posts section 1-2.

In addition to formal qualifications in teaching at university level, you must document

For appointment as a professor, an academic level conforming to establishednational standardsis required

The position of Associate Professor within obesity and metabolism requires that you meet the criteria in theRegulations concerning appointment and promotion to teaching and research posts section 1-4.

You will be expected to deliver high-quality teaching at undergraduate and postgraduate levels, and undertake supervision of Masters and Doctoral candidates. Evaluation of these skills will be based on documented experience and relevant teaching qualifications. Applicants with teaching experience at university level are preferred. Quality and breadth of the teaching qualifications will be evaluated.

NTNU is committed to following evaluation criteria for research quality according toThe San Francisco Declaration on Research Assessment - DORA.This means that we pay special attention to the quality and professional breadth of these works. We also consider experience from research management and participation in research projects.

You must document relevant basic competence forteaching and supervision at university/higher education-level. If this cannot be documented, you are required to complete an approved course in university teaching within two years of commencement. NTNU offers qualifying courses.

It is a prerequisite that within three years of appointment, new employees who do not speak a Scandinavian language can demonstrate skills in Norwegian or another Scandinavian language equivalent to level three in thecourse for Norwegian for speakers of other languages at the Department of Language and Literature at NTNU.

Please see theRegulations concerning appointment and promotion to teaching and research posts for general criteria for the position.

Preferred selection criteria

Personal characteristics

In the assessment of the best qualified applicant, we will emphasize education, experience and personal suitability as well as your motivation for the position.

We offer

Salary and conditions

In a position as professor (code 1013) you will normally be remunerated from gross NOK 704 900,- to NOK 900 000,- per year,depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

In a position as associate professor (code 1011) you will normally be remunerated from gross NOK 573 100,- to NOK 704 900,- per year,depending on qualifications and seniority. From the salary, 2% is deducted as a contribution to the Norwegian Public Service Pension Fund.

The engagement is to be made in accordance with the regulations in force concerning State Employees and Civil Servants, and the acts relating to Control of the Export of Strategic Goods, Services and Technology. Candidates who by assessment of the application and attachment are seen to conflict with the criteria in the latter law will be prohibited from recruitment to NTNU. After the appointment you must assume that there may be changes in the area of work.

It is a prerequisite that you can be present at and accessible to the institution on a daily basis.

About the application

The application and supporting documentation must be in English.

Please note that applications are only evaluated based on the information available on the application deadline. You should ensure that your application shows clearly how your skills and experience meet the criteria which are set out above.

If, for any reason, you have taken a career break or have had an atypical career and wish to disclose this in your application, the selection committee will take this into account, recognizing that the quantity of your research may be reduced as a result.

The application must include:

Joint works will be considered. If it is difficult to identify your contribution to joint works, you must attach a brief description of your participation.

Your application will be considered by an expert committee and the most suitable applicants will be invited to interview and to deliver a lecture.

General information

A good working environment is characterized by diversity. We encourage qualified candidates to apply, regardless of their gender, functional capacity or cultural background. NTNU wishes to increase the proportion of women in its academic positions, and women are therefore encouraged to apply.

As an employee at NTNU, you must at all times adhere to the changes that the development in the subject entails and the organizational changes that are adopted.

Under the Freedom of Information Act (offentleglova), your name, age, position and municipality may be made public even if you have requested not to have your name entered on the list of applicants.

If you have any questions about the position, please contact head of department Torstein Baade R, telephone +47 99 61 40 25, emailtorstein.ro@ntnu.no. If you have any questions about the recruitment process, please contact Yngve Lorentzen, e-mail:yngve.lorentzen@ntnu.no

Please submit your application and supporting documentation via jobbnorge.no.

Application deadline: 15.09.2020

The city of Trondheimis a modern European city with a rich cultural scene. Trondheim is the innovation capital of Norway with a population of 200,000. The Norwegian welfare state, including healthcare, schools, kindergartens and overall equality, is probably the best of its kind in the world. Professional subsidized day-care for children is easily available. Furthermore, Trondheim offers great opportunities for education (including international schools) and possibilities to enjoy nature, culture and family life and has low crime rates and clean air quality.

NTNU - knowledge for a better world

The Norwegian University of Science and Technology (NTNU) creates knowledge for a better world and solutions that can change everyday life.

The Faculty of Medicine and Health Sciences (MH) is one of NTNUs largest faculties with about 1800 employees (

1300 full-time equivalents). The Facultys main activities are education and research in close integration with St Olavs Hospital. For further information, see:https://www.ntnu.edu/mh.

Deadline15th September2020EmployerNTNU - Norwegian University of Science and TechnologyMunicipalityTrondheimScopeFulltimeDurationPermanentJobbnorge ID186952

Read the original here:
Professor/Associate Professor in Medicine Obesity and Metabolism job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 223116 - Times...

Posted in Molecular Medicine | Comments Off on Professor/Associate Professor in Medicine Obesity and Metabolism job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY – NTNU | 223116 – Times…

Page 39«..1020..38394041..5060..»